SecBot SecBot

LYEL

Lyell Immunopharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001806952 Biotech & Drug Discovery
$14.65 +0.35 (+2.45%)
Nov 16 4:00 PM ET · prev $14.30
Market cap
$384.5M
Small cap
Consensus
Buy
86% Buy or better · 14 analysts
Median target
🔒 Subscribers only
1 year
−15.9%
from $17.42 · Nov 17
30 days
+66.5%
from $8.80
52-week range
$7.51–38.60
−62% from high · low Oct 13
Avg volume 20D
240.0K
Nov 4 spike 1.10M
Short interest
1.41M
≈5.7% of shares · +0.8%
Days to cover
10.4
at average volume
Insider net
+$74.5M
2 buyers · 7 sellers · since Feb 10
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 8/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $75.0M at an average $13.35. 7 insiders sold $538.6K. Price is 10% above their cost.

  • InstitutionsBULLISH

    Q3 2026: 20 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    12 of 14 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.610 → −$1.570 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.8% to 1.41M shares. 10.4 days to cover, ≈5.7% of shares.

  • TrendUPTREND

    33% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCADD189,122$1.9M
Qube Research & Technologies LtdADD142,401$1.4M
MORGAN STANLEYDOUBLED89,423$875.5K
UBS Group AGDOUBLED84,141$823.7K
JPMORGAN CHASE & CODOUBLED49,608$477.7K
DIMENSIONAL FUND ADVISORS LPTRIM46,434$454.2K
RHUMBLINE ADVISERSADD25,787$252.4K
BNP PARIBAS FINANCIAL MARKETSDOUBLED25,411$248.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 86% rate it Buy or better
Strong Buy4Buy8Hold1Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 3, 2026Needham
REITERATE
REITERATEBuy
Sep 11, 2026Needham
REITERATE
REITERATEBuy
Aug 6, 2026Stifel
INITIATE
INITIATEBuy
Jul 22, 2026B. Riley Securities
INITIATE
INITIATEBuy
Jun 15, 2026Citizens
REITERATE
REITERATEMarket Outperform

Insider ledger

Form 4
$75.0M
bought · 2 insiders
$538.6K
sold · 7 insiders
+9.8%
vs their $13.35 cost
DateInsiderTypeValue
Nov 10, 2026
Bulis Veronica Sanchez
VP, Corporate Controller
Nov 10, 2026
SELL$6.6K
Nov 10, 2026
Seely Lynn
President and CEO
Nov 10, 2026
SELL$8.7K
Nov 10, 2026
Hill Stephen J.
Chief Operating Officer
Nov 10, 2026
SELL$1.4K
Nov 10, 2026
Lee Gary K.
Chief Scientific Officer
Nov 10, 2026
SELL$2.1K
Nov 4, 2026
ARCH Venture Fund XIII, L.P.
10%+ Owner
Nov 4, 2026
BUY$25.0M
Nov 4, 2026
ARCH Venture Partners IX, LLC
10%+ Owner
Nov 4, 2026
BUY$25.0M
Oct 12, 2026
Aguirre Jarrad Mattieu
Chief Medical Officer
Oct 12, 2026
SELL$3.6K
Sep 10, 2026
Aguirre Jarrad Mattieu
Chief Medical Officer
Sep 10, 2026
AWARD47,500 sh

Earnings setup

Estimates
−$1.57
EPS estimate, this quarter
+2%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.57-$1.57–-$1.57+2.5%$6.7K
Next Q-$1.69-$1.79–-$1.61+20.3%$5.0K
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
1,409,625
shares short
+0.8%
vs prior settlement
10.4
days to cover
≈5.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

15 filings · 6 press releases · 3 bullish · 1 bearish · 1 mixed · 10 neutral
All LYEL filing & press-release reports (21)